Eric Crombez - Mar 1, 2024 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: EVP and Chief Medical Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Stock symbol: RARE
Transactions as of: Mar 1, 2024
Transactions value $: -$66,555
Form type: 4
Date filed: 3/5/2024, 08:10 PM
Previous filing: Sep 29, 2023
Next filing: Apr 19, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Award	$0	+19.4K	+63.58%	$0.00	49.9K	Mar 1, 2024	Direct	F1
transaction	RARE	Common Stock	Sale	-$66.6K	-1.24K	-2.47%	$53.76	48.9K	Mar 1, 2024	Direct	F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Option (Right to Buy)	Award	$0	+34.2K		$0.00	34.2K	Mar 1, 2024	Common Stock	34.2K	$53.69	Direct	F5
transaction	RARE	Stock Option (Right to Buy)	Award	$0	+2.35K		$0.00	2.35K	Mar 1, 2024	Common Stock	2.35K	$67.37	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2	Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F3	Includes 253 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2023.
F4	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F5	On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
F6	On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On March 1, 2024, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 1,568 shares on that date.